We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Idecabtagene Vicleucel

News List

Ide-cel provides lasting remissions in multiply-relapsed myeloma europeanpharmaceuticalreview
February 26, 2021
BMS and bluebird bio have applied to the FDA for approval of ide-cel as a standard therapy for relapsed or refractory multiple myeloma based on positive Phase II trial results.
Bristol Myers Squibb and bluebird bio Announce Submission of Biologics License Application (BLA) to FDA for Idecabtagene Vicleucel for Adults with Relapsed and Refractory Multiple Myeloma drugs.com
September 23, 2020
Bristol Myers Squibb (NYSE: BMY) and bluebird bio, Inc. (Nasdaq: BLUE) today announced the submission of their Biologics License Application (BLA) to the U.S.
Bristol Myers Squibb and bluebird bio submit BLA for Idecabtagene Vicleucel to FDA pharmaceutical-business-review
April 03, 2020
Bristol Myers Squibb and bluebird bio submitted their Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA).